There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and IsoRay (ISR) with bullish sentiments.
Alkermes (ALKS)
Mizuho Securities analyst Vamil Divan maintained a Buy rating on Alkermes yesterday and set a price target of $28.00. The company’s shares closed last Wednesday at $19.50.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.3% and a 46.4% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Alkermes with a $21.56 average price target.
See today’s analyst top recommended stocks >>
IsoRay (ISR)
Oppenheimer analyst Suraj Kalia reiterated a Buy rating on IsoRay yesterday and set a price target of $1.50. The company’s shares closed last Wednesday at $1.42.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 9.0% and a 57.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
Currently, the analyst consensus on IsoRay is a Moderate Buy with an average price target of $1.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
